Clinical Trial

Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer

Name: Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer — clinical trial record (NCT06409429)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2/3

View on ClinicalTrials.gov →

Summary

This is a prospective, multicenter, randomized, double-blind, placebo-controlled study. The main purpose of the study is to evaluate the clinical efficacy and safety of Nimotuzumab combined with GX for postoperative adjuvant treatment of pancreatic cancer.

Trial Details

NCT Number	NCT06409429
Lead Sponsor	Tianjin Medical University Cancer Institute and Hospital
Conditions	Pancreatic Cancer
Enrollment	146 participants
Start Date	2024-05-01
Primary Completion	2027-05-30 (estimated)
Study Completion	2027-05-30 (estimated)
Updated on ClinicalTrials.gov	2024-05-10